Drug intelligence / Profile preview

JNJ-87189401

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

JNJ-87189401 is a bispecific antibody designed to target both prostate-specific membrane antigen (PSMA), a tumor-associated antigen highly expressed in prostate cancer cells, and CD28, a co-stimulatory molecule on T-cells. By binding to PSMA on tumor cells and CD28 on T-cells simultaneously, the drug aims to enhance T-cell activation and anti-tumor immune responses specifically against prostate cancer. It is being developed for the treatment of advanced prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). The drug is currently in Phase 1 clinical trials as part of combination therapy with another bispecific antibody (JNJ-78278343) targeting KLK2-CD3. The developer is Janssen Research & Development LLC, part of Johnson & Johnson[1][2][3][4][5][7].

Other names: anti-PSMA/anti-CD28 bispecific antibody

Targets

PSMA (Prostate-specific membrane antigen)CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on JNJ-87189401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-87189401.

Explore the full profile